Citadel Advisors
KRTX

Citadel Advisors’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Citadel Advisors’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-158,012
Closed -$50M – 15740
2023
Q4 		$50M Sell
158,012
-31,585
-17% -$6.14M 0.01% 1184
2023
Q3 		$32.1M Buy
189,597
+94,863
+100% +$17.8M 0.01% 1444
2023
Q2 		$20.5M Buy
+94,734
New +$20.3M ﹤0.01% 1849
2023
Q1 		– Sell
-28,168
Closed -$5.39M – 15800
2022
Q4 		$5.54M Sell
28,168
-55,673
-66% -$11.9M ﹤0.01% 3683
2022
Q3 		$18.9M Buy
83,841
+64,222
+327% +$13M ﹤0.01% 1936
2022
Q2 		$2.48M Buy
19,619
+2,931
+18% +$337K ﹤0.01% 5123
2022
Q1 		$2.12M Buy
16,688
+9,313
+126% +$1.05M ﹤0.01% 5970
2021
Q4 		$966K Sell
7,375
-4,066
-36% -$526K ﹤0.01% 8054
2021
Q3 		$1.4M Buy
11,441
+9,629
+531% +$1.11M ﹤0.01% 7278
2021
Q2 		$207K Buy
+1,812
New +$212K ﹤0.01% 12090
2021
Q1 		– Sell
-26,236
Closed -$2.97M – 13863
2020
Q4 		$2.67M Buy
26,236
+17,226
+191% +$1.6M ﹤0.01% 4779
2020
Q3 		$696K Buy
9,010
+1,595
+22% +$136K ﹤0.01% 6702
2020
Q2 		$826K Sell
7,415
-76,336
-91% -$6.64M ﹤0.01% 6183
2020
Q1 		$6.03M Buy
83,751
+79,099
+1,700% +$6.76M ﹤0.01% 2478
2019
Q4 		$351K Sell
4,652
-73,721
-94% -$3.23M ﹤0.01% 7347
2019
Q3 		$1.28M Sell
78,373
-47,625
-38% -$925K ﹤0.01% 5179
2019
Q2 		$2.52M Buy
+125,998
New +$2.52M ﹤0.01% 4129

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Citadel Advisors's KRTX Position: Q1 2024 in Review

Citadel Advisors sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 158,012 shares — an estimated $50M sold.

Citadel Advisors first reported a position in KRTX in Q2 2019 and held it in 17 quarters. The position peaked at $50M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Citadel Advisors reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 158,012 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $50M.
  • Citadel Advisors first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 17 quarters.
  • Citadel Advisors's Karuna Therapeutics, Inc. Common Stock position peaked at $50M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.